Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

899
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
899
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Abnormal Proliferation02:23

Abnormal Proliferation

4.9K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

13.6K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
13.6K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

2.3K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study.

medRxiv : the preprint server for health sciences·2026
Same author

Waldenstrom Macroglobulinemia Leading to Cholestatic Liver Injury and Rapid Progression to Liver Failure.

ACG case reports journal·2026
Same author

Impact of baseline osseous involvement on outcomes in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia.

Blood neoplasia·2026
Same author

Real-world treatment patterns, patient characteristics, and outcomes of initial cBTKi-based therapies in second-line or later amongst a contemporary cohort of patients with MCL in the United States.

Leukemia & lymphoma·2026
Same author

MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.

Blood advances·2026
Same author

Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Related Experiment Video

Updated: Nov 27, 2025

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

596

Novel targets in aggressive lymphoma.

Kami Maddocks1

  • 1The Ohio State University, Columbus, OH.

Hematology. American Society of Hematology. Education Program
|December 4, 2020
PubMed
Summary

New immunotherapies offer hope for aggressive B-cell lymphomas that resist standard treatment. Chimeric antigen receptor T-cell therapies and antibody drug conjugates show promise for improving survival in relapsed or refractory disease.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Chemoimmunotherapy with rituximab improves survival for aggressive B-cell lymphomas, but relapsed or refractory disease carries a poor prognosis.
  • Novel agents have shown efficacy in relapsed disease, yet randomized trials on chemoimmunotherapy backbones have not demonstrated further survival benefits.
  • Recent advancements focus on harnessing the patient's immune system for treating relapsed or refractory aggressive lymphomas.

Purpose of the Study:

  • To discuss promising targets in aggressive lymphoma with the greatest potential for improving patient outcomes.
  • To highlight novel therapies, their toxicities, and their potential roles in initial or subsequent treatment regimens.

Main Methods:

  • Review of recent advancements in treating relapsed or refractory aggressive B-cell lymphomas.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.6K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.4K

Related Experiment Videos

Last Updated: Nov 27, 2025

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

596
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.6K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.4K
  • Discussion of novel therapeutic agents, including chimeric antigen receptor T-cells and antibody drug conjugates.
  • Analysis of targeted agents and their potential use in combination therapies.

    • Main Results:

    • Chimeric antigen receptor T-cell therapies offer potential curative options, despite challenges with toxicity and access.
    • The antibody drug conjugate polatuzumab combined with chemoimmunotherapy provides survival benefits for patients unsuitable for aggressive treatments.
    • Several targeted agents demonstrate efficacy but often require durable responses through combination therapies.

    Conclusions:

    • Emerging immunotherapies and targeted agents represent significant progress in managing relapsed or refractory aggressive lymphomas.
    • These novel approaches, including CAR T-cell therapy and antibody drug conjugates, have the potential to alter the standard of care.
    • Further research into combination therapies is crucial for achieving durable responses and improving long-term outcomes for patients with aggressive lymphomas.